Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
435 Leser
Artikel bewerten:
(1)

Sanity Group GmbH: Sanity Group survey: Almost 81 percent support legalisation of cannabis in various forms

DGAP-Media / 2020-04-09 / 10:29 
 
Federal states in which the majority of respondents support the medical use 
of cannabis have a majority in the Bundesrat. 47.8 percent of women are in 
favor of legalizing cannabis for medical purposes, 44.5 percent of men are 
in favor of the complete legalization of cannabis with regulation and 
taxation. A majority of parents are in favor of allowing the medical use of 
cannabis. 
 
"We at the Sanity Group value open, social debate and are constantly 
striving to find and implement ways to improve social well-being. Thanks to 
its proven positive effects in many cases, we believe that cannabis has a 
strong potential, both medically for society and, as a consequence, for the 
improvement of health for the national economy. According to the European 
Cannabis Report (4th edition), the European cannabis industry has a 
potential total market value of 123 billion euros by 2028. That is why we 
wanted to broaden the discussion by providing reliable data and insights 
into the overall social perception in Germany," says Finn Hänsel, Managing 
Director of the Sanity Group GmbH. 
 
The majority of respondents in all German states support the legalization of 
cannabis to a certain extent. In this context, federal states in which the 
majority of participants support the medical use of cannabis have a total 
share of more than half of the seats in the Federal Council, the 
distribution of which depends on the population. 
 
Among the male and female respondents, the results show that the majority at 
least advocates the medical legalization of cannabis. 35.3 percent of men 
support the current legal status of cannabis on medical prescription, with 
the larger group and almost half of the male voters (44.5 percent) support 
the complete legalization of cannabis with regulation and taxation. 
 
While the majority of women are generally against the criminalization of 
cannabis, their results show the opposite of male voters in terms of the 
extent of legality: 47.8 percent of the respondents support the legalization 
of cannabis for medical purposes, while 32 percent of women support the full 
legalization of cannabis. 
 
Parents are generally positive about cannabis: 38 percent of this population 
group supports the legalization and taxation of cannabis, which is 3.5 
percent more than those who support cannabis as medicine (34.5 percent). 
Childless people speak out in favor of cannabis with a proportion of 38.2 
percent favors legalization of cannabis where regulation and taxation exist, 
while medically prescribed cannabis is preferred with 44.1 percent. 
 
This survey was conducted through Civey, an external opinion polling 
platform with machine learning technology. For this purpose, an online 
survey network of more than 25,000 websites (URLs) was used by Civey 
Riversampling to obtain the opinion of users around the clock. Civey relies 
on nonprobability samples and has developed a procedure to compensate for 
possible distortions. The survey responses were analyzed to verify that the 
user is a real person, provides sufficient information and measures the 
possibility that his or her answer is truthful. 
 
A quoted sample of approximately 5,000 respondents is drawn based on 
variables such as age, gender, voting intention for the Bundestag election, 
time of voting, and place of voting to ensure that a minimum number of 
respondents from each population group were considered. Thus the survey is 
considered representative. Finally, the votes in the sample are re-weighted 
according to other socio-demographic aspects such as age, gender, marital 
status, population density, purchasing power and party preference to correct 
any remaining distortions. Finally, the weighting of the data is based on 
the official population data, which are obtained from the Federal 
Statistical Office or the Federal Election Commissioner. 
 
About the Sanity Group 
 
The Sanity Group and its subsidiaries develop innovative cannabinoid-based 
pharmaceuticals as well as wellness and cosmetic products and make them 
easily accessible throughout Europe. To exploit the full potential of their 
health benefits, the Sanity Group invests in basic research on the cannabis 
plant and its active ingredients, as well as in specific areas of 
application. Equipped with this knowledge, the Sanity Group's team of 
experts continuously educates healthcare professionals, patients, and 
consumers and supports them in leading a healthier life. www.sanitygroup.com 
 
End of Media Release 
 
Issuer: Sanity Group GmbH 
Key word(s): Health 
 
2020-04-09 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
1019401 2020-04-09 
 
 

(END) Dow Jones Newswires

April 09, 2020 04:29 ET (08:29 GMT)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.